Non-viral Transposon
Non-viral Transposon - Related Videos
02:57
DNA-only Transposons
0 Views •
2020
DNA-only transposons are called autonomous transposons since they code for the enzyme transposase that is required for the transposition mechanism. Insertion of transposons can alter gene functions in multiple ways. They can mutate the gene, alter gene expression by introducing a novel promoter or insulator sequence, introduce new splice sites, and change the mRNA transcripts produced, or remodel chromatin structure. The donor site from where the transposon is excised is either degraded or...
10:02
piggyBac Transposon System Modification of Primary Human T Cells
0 Views •
Cited by 16 •
2012
We describe a method to genetically modify primary human T cells with a transgene using the non-viral piggyBac transposon system. T cells modified to using the piggyBac transposon system exhibit stable transgene expression.
03:29
PiggyBac Transposon-Mediated Gene Editing in Human iPSCs: A Procedure to Integrate Gene of Interest in Human iPSCs Using PiggyBac Transposon System
0 Views •
2025
This video demonstrates the procedure to generate motor neurons by transfection of human iPSCs with PiggyBac transposon system by the ectopic expression of lineage-specific transcription factors.
02:52
Isolation of Gram-Negative Bacteria with Genomic Transposon Insertions
0 Views •
2025
Source: Kazi, M. I., et. al., Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing. J. Vis. Exp. (2020)This video demonstrates the selection, quantification, and preservation of Gram-negative recipient bacteria carrying transposon insertions based on kanamycin resistance.
01:24
Transposons
0 Views •
2025
Transposons, or "jumping genes," are small mobile genetic elements (MGEs) that range from 700 to 40,000 base pairs in length. They are found in all organisms and can move within the same chromosome or transfer to different chromosomes. In some cases, transposons can also jump between different host DNA molecules, such as plasmids or viruses, contributing to genetic variability.Barbara McClintock first discovered these mobile genetic elements in the 1940s while studying maize genetics, and she...
FAQs
Terminal repeat sequences flank the therapeutic or research gene and provide the recognition sites for transposase. This enzyme uses those sequences to identify the intended genetic cargo, excise it from a donor construct, and support its insertion into host-cell genomic DNA. Their position around the cargo therefore connects transposase activity with stable genomic gene delivery.
Transposase first recognizes the terminal repeats surrounding the inserted gene, then helps remove that transposon from its donor construct and integrate it into genomic DNA. Once the genetic material becomes part of the host-cell genome, immune cells can maintain gene expression rather than relying only on the original delivery construct. This supports durable immune-cell engineering studies.
The main distinction is that this approach delivers genetic material without relying on a viral vector. That difference gives researchers a flexible platform for immune-cell and other target-cell studies while supporting scalability, manufacturing control, and safety assessment. It is especially relevant when experimental designs require stable gene expression alongside closer control of how the delivery system is produced and evaluated.
A typical workflow places the therapeutic or research gene between terminal repeat sequences in a donor construct and supplies the transposase enzyme to the target cells. The enzyme recognizes the repeats, excises the transposon, and integrates the cargo into genomic DNA. Researchers can then examine stable gene expression in immune cells or other selected target cells.
Stable genetic modification of immune cells enables experiments that examine engineered cellular behavior over time. In immunology and infection research, the approach can support studies of host-pathogen interactions, vaccine development, and cellular immunotherapies. Its usefulness comes from combining genomic insertion with a non-viral delivery format, allowing researchers to investigate immune functions or therapeutic designs in modified cells.
Beyond genomic insertion, the platform may offer advantages in scalability and manufacturing control compared with approaches that depend on viral vectors. These features can help organize production and support safety assessment as researchers develop immune-cell engineering, vaccine, or cellular immunotherapy applications. The resulting system is useful both for exploratory experiments and for evaluating how a delivery strategy may translate into broader research workflows.